Immusoft’s MPS 1 CGT therapeutic hurdles traditional barriers, eliminating patient preconditioning and enabling redosing.

CHICAGO, IL—RBT-1, a novel pharmacologic approach to preconditioning, appeared beneficial in patients undergoing CABG and/or valve surgery in an interim analysis of the phase II START trial. The ...